Dermatology Times: June 22, 2025

12345678910111213141516
Across
  1. 4. This light-based therapy was combined with ritlecitinib to accelerate repigmentation in nonsegmental vitiligo.
  2. 8. Nearly half of patients with this autoimmune hair loss disorder responded to ritlecitinib.
  3. 9. Peter Lio, MD, emphasized the importance of safety and precision medicine in pediatric management of this condition.
  4. 10. Patients with the generalized pustular form of this disease may face up to 5 times higher mortality risk.
  5. 12. This cytokine is a therapeutic target for psoriasis and is blocked by several biologics.
  6. 13. The INTEGUMENT trial studied atopic dermatitis treatment in this age group using roflumilast 0.05% cream.
  7. 14. This type of language in dermatology may improve outcomes for LGBTQ+ patients, especially those with acne.
  8. 15. This JAK inhibitor was discussed at RAD 2025 for its role in pediatric atopic dermatitis.
  9. 16. The Clean Slate Program at UCSD offers free laser removal of this form of body art to support social reintegration.
Down
  1. 1. This JAK1 inhibitor has shown long-term remission in treatment-resistant bullous pemphigoid.
  2. 2. This oral JAK3/TEC family inhibitor is used for vitiligo and alopecia areata with sustained results in some patients.
  3. 3. This PDE4 inhibitor shows promise as a steroid-free treatment for infant atopic dermatitis.
  4. 5. The VALIANT survey highlighted high rates of depression in patients with this pigmentary disorder.
  5. 6. (Abbreviation) A German study explored the emotional burden of this occupational eczema affecting the hands.
  6. 7. This mental health condition was reported at high rates in individuals living with vitiligo.
  7. 11. This AI-powered tool helps visualize potential outcomes of skin care treatments using real patient images.